Vericel Corporation VCEL
Vericel Corporation (Nasdaq: VCEL) is a drug developer. Its lead program, MASCOT (MACI for ankle), is in Phase 3 for Osteochondral lesions of the talus. Its next catalyst on record is MACI (UK): MHRA approval and UK commercialization (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MACI (UK) — MHRA approval and UK commercialization (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MACI (knee) | Cartilage defects of the knee | cell therapy | Approved |
| Epicel | Deep-dermal or full-thickness burns ≥30% TBSA | cell therapy | Approved |
| NexoBrid | Eschar removal in thermal burns | protein/peptide | Approved |
| MASCOT (MACI for ankle) | Osteochondral lesions of the talus | cell therapy | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.